graph EGM comparisons
atezolizumab alonetitlenivolumab alonetitledurvalumab alonetitlepembrolizumab alonetitlenivolumab plus SoCtitledurvalumab plus tremelimumabtitleatezolizumab plus carboplatin plus nab-paclitaxeltitleatezolizumab plus bevacizumab plus carboplatin plus paclitaxeltitlecemiplimabtitleatezolizumab plus carboplatin plus paclitaxeltitlenivolumab plus ipilimumabtitleavelumab alonetitlepembrolizumab plus SoCtitlepembrolizumab (10mg/kg)titlepembrolizumab (2mg/kg)titleTislelizumabtitleatezolizumab plus pemetrexed and platintitlenivolumab plus ipilimumab plus SoCtitlesintillimab plus SoCtitlepembrolizumab plus ipilimumabtitledurvalumab plus osimertinibtitleipilimumab plus SoCtitlepembrolizumab and pemetrexed plus platintitlepembrolizumab plus placebotitlenab-paclitaxeltitleStandard of Care (SoC)titleosimertinibtitlecarboplatin plus nab-paclitaxeltitleplacebo plus SoCtitlepemetrexed plus platintitlebevacizumab plus carboplatin and paclitaxeltitleplacebotitledocetaxeltitlePACIFIC, 2017 NCT02125461 laNSCLC - M - all population 476/237CheckMate 816, 2022 NCT02998528 locally advanced NSCLC - (neo)adjuvant (NA) 179/179EMPOWER lung1 (all population), 2021 NCT03088540 mNSCLC - L1 - all population 356/354MYSTIC (D ; all population), 2020 NCT02453282 mNSCLC - L1 - all population 374/372MYSTIC (DT ; all population), 2020 NCT02453282 mNSCLC - L1 - all population 372/372CheckMate 9LA, 2021 NCT03215706 mNSCLC - L1 - all population 361/358ORIENT-11, 2020 NCT03607539 mNSCLC - L1 - all population 266/131CheckMate 227 (NC vs C ; PDL1<1%), 2018 NCT02477826 mNSCLC - L1 - PDL1 negative 177/186IMpower-110 (TC2/3 or IC2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 166/162IMpower-110 (TC1/2/3 or IC1/2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 277/277IMpower-110 (TC3 or IC3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 107/98EMPOWER lung1 (PDL1>50%), 2021 NCT03088540 mNSCLC - L1 - PDL1 positive 283/280MYSTIC (D ; PDL1>25%), 2020 NCT02453282 mNSCLC - L1 - PDL1 positive 163/162MYSTIC (DT ; PDL1>25%), 2020 NCT02453282 mNSCLC - L1 - PDL1 positive 163/162CheckMate 026 (PDL1>5%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 211/212CheckMate 026 (PDL1>1%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 271/270CheckMate 227 (NI vs C ; PDL1>1%), 2018 NCT02477826 mNSCLC - L1 - PDL1 positive 396/397KEYNOTE-024 (PDL1>50%), 2016 NCT02142738 mNSCLC - L1 - PDL1 positive 154/151KEYNOTE-042 (PDL1>50%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 299/300KEYNOTE-042 (PDL1>20%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 413/405KEYNOTE-042 (PDL1>1%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 637/637KEYNOTE-598, 2020 NCT03302234 mNSCLC - L1 - PDL1 positive 284/284CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 NCT02477826 mNSCLC - L1 - TMB>10Mb 139/160OAK (all population), 2016 NCT02008227 mNSCLC - L2 - all population 613/612POPLAR, 2016 NCT01903993 mNSCLC - L2 - all population 144/143JAVELIN Lung 200 (all population), 2018 NCT02395172 mNSCLC - L2 - all population 396/396CheckMate 078, 2019 NCT02613507 mNSCLC - L2 - all population 338/166RATIONALE 303, 0 NCT03358875 mNSCLC - L2 - all population -9/-9CAURAL (EXPLORATORY), 2019 NCT02454933 mNSCLC - L2 - EGFR mutant 14/15ARCTIC (DT ; study B ; PDL1<25%), 2020 NCT02352948 mNSCLC - L2 - PDL1 negative 174/118OAK (PDL1 TC 1/2/3), 2016 NCT02008227 mNSCLC - L2 - PDL1 positive 347/337JAVELIN Lung 200 (PDL1 >1%), 2018 NCT02395172 mNSCLC - L2 - PDL1 positive 264/265ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 NCT02352948 mNSCLC - L2 - PDL1 positive 62/64KEYNOTE-010 (P:10 mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 346/343KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 151/152KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 139/152KEYNOTE-010 (P: 2mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 344/343IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 NCT02366143 non squamous - mNSCLC - L1 - all population 400/400IMpower-130 (all population), 2019 NCT02367781 non squamous - mNSCLC - L1 - all population 483/240IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 NCT02366143 non squamous - mNSCLC - L1 - all population 402/400IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 155/129IMpower-150 (ABCP vs BPC WT), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 356/336IMpower-130 (WT), 2019 NCT02367781 non squamous - mNSCLC - L1 - Wild Type (WT) 451/228IMpower-132 (WT), 0 NCT02657434 non squamous - mNSCLC - L1 - Wild Type (WT) 292/286KEYNOTE-021, 2016 NCT02039674 non squamous - mNSCLC - L1 - Wild Type (WT) 60/63KEYNOTE-189, 2018 NCT02578680 non squamous - mNSCLC - L1 - Wild Type (WT) 410/206CheckMate 057, 2015 NCT01673867 non squamous - mNSCLC - L2 - all population 292/290CheckMate 816, 2022 NCT02998528 NSCLC neoadjuvant setting 179/179IMpower-131 (ACnP), 2020 NCT02367794 squamous - mNSCLC - L1 - all population 343/340IMpower-131 (ACP) EXPLORATORY, 2020 NCT02367794 squamous - mNSCLC - L1 - all population 338/340CA184-104, 2017 NCT01285609 squamous - mNSCLC - L1 - all population 479/477KEYNOTE-407, 2018 NCT02775435 squamous - mNSCLC - L1 - all population 278/281CheckMate 017, 2015 NCT01642004 squamous - mNSCLC - L2 - all population 135/137

Pathology:  laNSCLC - M - all population;   locally advanced NSCLC - (neo)adjuvant (NA);   mNSCLC - L1 - all population;   mNSCLC - L1 - PDL1 negative;   mNSCLC - L1 - PDL1 positive;   mNSCLC - L1 - TMB>10Mb;   mNSCLC - L2 - all population;   mNSCLC - L2 - EGFR mutant;   mNSCLC - L2 - PDL1 negative;   mNSCLC - L2 - PDL1 positive;   non squamous - mNSCLC - L1 - all population;   non squamous - mNSCLC - L1 - Wild Type (WT);   non squamous - mNSCLC - L2 - all population;   NSCLC neoadjuvant setting;   squamous - mNSCLC - L1 - all population;   squamous - mNSCLC - L2 - all population; 

laNSCLC - M - all populationlocally advanced NSCLC - (neo)adjuvant (NA)mNSCLC - L1 - all populationmNSCLC - L1 - PDL1 negativemNSCLC - L1 - PDL1 positivemNSCLC - L1 - TMB>10MbmNSCLC - L2 - all populationmNSCLC - L2 - EGFR mutantmNSCLC - L2 - PDL1 negativemNSCLC - L2 - PDL1 positivenon squamous - mNSCLC - L1 - all populationnon squamous - mNSCLC - L1 - Wild Type (WT)non squamous - mNSCLC - L2 - all populationNSCLC neoadjuvant settingsquamous - mNSCLC - L1 - all populationsquamous - mNSCLC - L2 - all population
PACIFIC, 2017CheckMate 816, 2022EMPOWER lung1 (all population), 2021MYSTIC (D ; all population), 2020MYSTIC (DT ; all population), 2020CheckMate 9LA, 2021ORIENT-11, 2020CheckMate 227 (NC vs C ; PDL1<1%), 2018IMpower-110 (TC2/3 or IC2/3), 2020IMpower-110 (TC1/2/3 or IC1/2/3), 2020IMpower-110 (TC3 or IC3), 2020EMPOWER lung1 (PDL1>50%), 2021MYSTIC (D ; PDL1>25%), 2020MYSTIC (DT ; PDL1>25%), 2020CheckMate 026 (PDL1>5%), 2016CheckMate 026 (PDL1>1%), 2016CheckMate 227 (NI vs C ; PDL1>1%), 2018KEYNOTE-024 (PDL1>50%), 2016KEYNOTE-042 (PDL1>50%), 2019KEYNOTE-042 (PDL1>20%), 2019KEYNOTE-042 (PDL1>1%), 2019KEYNOTE-598, 2020CheckMate 227 (NI vs C ; TMB >10 Mb), 2018OAK (all population), 2016POPLAR, 2016JAVELIN Lung 200 (all population), 2018CheckMate 078, 2019RATIONALE 303, 0CAURAL (EXPLORATORY), 2019ARCTIC (DT ; study B ; PDL1<25%), 2020OAK (PDL1 TC 1/2/3), 2016JAVELIN Lung 200 (PDL1 >1%), 2018ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020KEYNOTE-010 (P:10 mg/kg), 2016KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg), 2016IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018IMpower-130 (all population), 2019IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018IMpower-150 (ABCP vs BPC WT), 2018IMpower-130 (WT), 2019IMpower-132 (WT), 0KEYNOTE-021, 2016KEYNOTE-189, 2018CheckMate 057, 2015CheckMate 816, 2022IMpower-131 (ACnP), 2020IMpower-131 (ACP) EXPLORATORY, 2020CA184-104, 2017KEYNOTE-407, 2018CheckMate 017, 2015
atezolizumab alone6T1T1T1T1T1T1
nivolumab alone5T1T1T1T1T1
durvalumab alone4T1T1T1T1
pembrolizumab alone4T1T1T1T1
nivolumab plus SoC3T1T1T1
durvalumab plus tremelimumab3T1T1T1
atezolizumab plus carboplatin plus nab-paclitaxel3T1T0T1T1
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel3T1T1T1
cemiplimab2T1T1
atezolizumab plus carboplatin plus paclitaxel2T1T1
nivolumab plus ipilimumab2T1T1
avelumab alone2T1T1
pembrolizumab plus SoC2T1T1
pembrolizumab (10mg/kg)2T1T1
pembrolizumab (2mg/kg)2T1T1
Tislelizumab1T1
atezolizumab plus pemetrexed and platin1T1
nivolumab plus ipilimumab plus SoC1T1
sintillimab plus SoC1T1
pembrolizumab plus ipilimumab1T1
durvalumab plus osimertinib1T1
ipilimumab plus SoC1T1
pembrolizumab and pemetrexed plus platin1T1
pembrolizumab plus placebo0T0
nab-paclitaxel0T0
Standard of Care (SoC)0T0T0T0T0T0T0T0T0T0T0T0T0T0T0T0T0T0T0
osimertinib0T0
carboplatin plus nab-paclitaxel0T0T0
placebo plus SoC0T0T0T0T0T0T0
pemetrexed plus platin0T0T0T0T0T0
bevacizumab plus carboplatin and paclitaxel0T0T0T0T0
placebo0T0
docetaxel0T0T0T0T0T0T0T0T0T0T0T0T0T0